Cargando…

Natural products: a hope for glioblastoma patients

Glioblastoma (GBM) is one of the most aggressive malignant tumors with an overall dismal survival averaging one year despite multimodality therapeutic interventions including surgery, radiotherapy and concomitant and adjuvant chemotherapy. Few drugs are FDA approved for GBM, and the addition of temo...

Descripción completa

Detalles Bibliográficos
Autores principales: Vengoji, Raghupathy, Macha, Muzafar A., Batra, Surinder K., Shonka, Nicole A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955138/
https://www.ncbi.nlm.nih.gov/pubmed/29774132
http://dx.doi.org/10.18632/oncotarget.25175
_version_ 1783323651055026176
author Vengoji, Raghupathy
Macha, Muzafar A.
Batra, Surinder K.
Shonka, Nicole A.
author_facet Vengoji, Raghupathy
Macha, Muzafar A.
Batra, Surinder K.
Shonka, Nicole A.
author_sort Vengoji, Raghupathy
collection PubMed
description Glioblastoma (GBM) is one of the most aggressive malignant tumors with an overall dismal survival averaging one year despite multimodality therapeutic interventions including surgery, radiotherapy and concomitant and adjuvant chemotherapy. Few drugs are FDA approved for GBM, and the addition of temozolomide (TMZ) to standard therapy increases the median survival by only 2.5 months. Targeted therapy appeared promising in in vitro monolayer cultures, but disappointed in preclinical and clinical trials, partly due to the poor penetration of drugs through the blood brain barrier (BBB). Cancer stem cells (CSCs) have intrinsic resistance to initial chemoradiation therapy (CRT) and acquire further resistance via deregulation of many signaling pathways. Due to the failure of classical chemotherapies and targeted drugs, research efforts focusing on the use of less toxic agents have increased. Interestingly, multiple natural compounds have shown antitumor and apoptotic effects in TMZ resistant and p53 mutant GBM cell lines and also displayed synergistic effects with TMZ. In this review, we have summarized the current literature on natural products or product analogs used to modulate the BBB permeability, induce cell death, eradicate CSCs and sensitize GBM to CRT.
format Online
Article
Text
id pubmed-5955138
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-59551382018-05-17 Natural products: a hope for glioblastoma patients Vengoji, Raghupathy Macha, Muzafar A. Batra, Surinder K. Shonka, Nicole A. Oncotarget Review Glioblastoma (GBM) is one of the most aggressive malignant tumors with an overall dismal survival averaging one year despite multimodality therapeutic interventions including surgery, radiotherapy and concomitant and adjuvant chemotherapy. Few drugs are FDA approved for GBM, and the addition of temozolomide (TMZ) to standard therapy increases the median survival by only 2.5 months. Targeted therapy appeared promising in in vitro monolayer cultures, but disappointed in preclinical and clinical trials, partly due to the poor penetration of drugs through the blood brain barrier (BBB). Cancer stem cells (CSCs) have intrinsic resistance to initial chemoradiation therapy (CRT) and acquire further resistance via deregulation of many signaling pathways. Due to the failure of classical chemotherapies and targeted drugs, research efforts focusing on the use of less toxic agents have increased. Interestingly, multiple natural compounds have shown antitumor and apoptotic effects in TMZ resistant and p53 mutant GBM cell lines and also displayed synergistic effects with TMZ. In this review, we have summarized the current literature on natural products or product analogs used to modulate the BBB permeability, induce cell death, eradicate CSCs and sensitize GBM to CRT. Impact Journals LLC 2018-04-24 /pmc/articles/PMC5955138/ /pubmed/29774132 http://dx.doi.org/10.18632/oncotarget.25175 Text en Copyright: © 2018 Vengoji et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Vengoji, Raghupathy
Macha, Muzafar A.
Batra, Surinder K.
Shonka, Nicole A.
Natural products: a hope for glioblastoma patients
title Natural products: a hope for glioblastoma patients
title_full Natural products: a hope for glioblastoma patients
title_fullStr Natural products: a hope for glioblastoma patients
title_full_unstemmed Natural products: a hope for glioblastoma patients
title_short Natural products: a hope for glioblastoma patients
title_sort natural products: a hope for glioblastoma patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955138/
https://www.ncbi.nlm.nih.gov/pubmed/29774132
http://dx.doi.org/10.18632/oncotarget.25175
work_keys_str_mv AT vengojiraghupathy naturalproductsahopeforglioblastomapatients
AT machamuzafara naturalproductsahopeforglioblastomapatients
AT batrasurinderk naturalproductsahopeforglioblastomapatients
AT shonkanicolea naturalproductsahopeforglioblastomapatients